Hold onto your hat. One of the frequent adverse side-effects observed during clinical trials of Namenda is tinnitus.
Other Adverse Events Observed During Clinical Trials
Special Senses:Frequent: cataract, conjunctivitis. Infrequent: macula lutea degeneration, decreased visual acuity, decreased hearing, tinnitus, blepharitis, blurred vision, corneal opacity, glaucoma, conjunctival hemorrhage, eye pain, retinal hemorrhage, xerophthalmia, diplopia, abnormal lacrimation, myopia, retinal detachment.
Here is a study -- it may be the same one Denver referred to above -- evaluating the efficacy of this drug to treat tinnitus.
The bottom line? No soap.
OBJECTIVE: To evaluate efficacy and safety of memantine in the treatment of tinnitus.
STUDY DESIGN: Prospective, randomized, double-blind crossover study.
SUBJECTS AND METHODS: A total of 60 patients with tinnitus were randomized into a double-blind, placebo-controlled, prospective crossover study. Patients each received up to 20 mg memantine and placebo for 90 days, separated by a 30-day washout period. Treatment effects were assessed by using the Tinnitus Handicap Inventory (THI). A total of 43 patients completed the trial.
RESULTS: There was no significant improvement of THI score after memantine treatment compared with placebo. A possible tendency for delayed effects of memantine was observed. The incidence of side effects during memantine treatment was 9.4 percent, leading to interruption of treatment in all cases.
CONCLUSION: This study does not provide evidence to recommend memantine for the treatment of tinnitus. A possible late effect of the drug should be evaluated in further studies with longer observation periods.http://www.druglib.com/abstract/fi/figueiredo-rr_otolaryngol-head-neck-surg_20080400.html Rob